VEGFR2/CD309 anticorps (pTyr1175) (FITC)

N° du produit ABIN746790

Cet anticorps anti-VEGFR2/CD309 est un anticorps Lapin Polyclonal détectant VEGFR2/CD309 dans WB. Adapté pour Humain, Souris et Rat.

Aperçu rapide pour VEGFR2/CD309 anticorps (pTyr1175) (FITC) (ABIN746790)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est conjugé à/à la FITC

Application: Western Blotting (WB)

Détail du produit anti-VEGFR2/CD309 anticorps (FITC)

Épitope: pTyr1175

Specificité: This phosphorylation site is homologous to that of Ser1173 in Mouse and Ser1171 in Rat.

Réactivité croisée: Souris, Rat

Homologie: Dog,Cow,Pig,Horse,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic phosphopeptide derived from human VEGFR2 around the phosphorylation site of Tyr1175

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: Vegfr2

Sujet:

Synonyms: FLK1, CD309, VEGFR, VEGFR2, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase insert domain receptor, KDR, Protein-tyrosine kinase receptor flk-1

Background: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

ID gène: 3791

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling